$ACON News

Aclarion Announces Texas Spine Care Center as New CLARITY Site

Aclarion Announces Texas Spine Care Center As New Clinical Site In Chronic Low bAck pain Randomized Independent Trial studY Trial

Aclarion Receives Notice Of Allowance For A U.S. Patent On Its Multi-Voxel Prescription For Lumbar Disc Evaluation

Aclarion to Present at the Planet MicroCap Las Vegas Powered by MicroCapClub

Aclarion Partners with PRIA Healthcare to Advance Reimbursement and Commercial Adoption of Its AI-Powered Nociscan Platform

Aclarion Launches Market Access Program In Partnership With PRIA Healthcare

Aclarion Rejects Echo Lake Capital’s Unsolicited Acquisition Proposal

Aclarion Stockholders Approve All Proposals at 2026 Annual Meeting

Aclarion Board Reviews Echo Lake's Unsolicited Public Proposal And Unanimously Determined To Reject It

Aclarion Adds Institute of Neuro Innovation to Support Nociscan Growth and Real-World Evidence Generation

Aclarion Partners With Institute of Neuro Innovation on Back Pain Technology

Aclarion Technology Demonstrates Potential Beyond Surgical Planning in New Immune-Biomarker Study

Aclarion Announces That Its Nociscan Technology Was Used In A New Research Study Exploring The Biological Factors Associated With Back Pain In Patients With Modic Type 1 Changes

Ascendiant Capital Maintains Buy on Aclarion, Raises Price Target to $7.5

Aclarion, Inc. Comments on Echo Lake Capital’s Letter and Unsolicited Proposal

Echo Lake Capital Offers To Acquire Aclarion Inc.

Echo Lake Capital Offers To Acquire Aclarion At $4.00/Share And Contingent Value Right Representing Right For Stockholders To Receive 80% Of Net Proceeds From Nociscan Sale.

Aclarion (ACON) Upgraded to Buy: Here's Why

Aclarion Q1 EPS $(1.34) Beats $(1.55) Estimate, Sales $21.140K Miss $25.000K Estimate

Aclarion Announces Addition of First Private Practice Site in Los Angeles into CLARITY Trial to Further Accelerate Enrollment